Physicochemical compatibility of pentoxifylline injection with high-concentration parenteral medications  

作　　者：S.M.D.K.Ganga Senarathna Tobias Strunk Michael Petrovski Sarah Woodland Kevin T.Batty 

机构地区：[1]Curtin Medical School,Curtin University,Bentley,Australia [2]Medical School,University of Western Australia,Crawley,Australia [3]Neonatal Directorate,King Edward Memorial Hospital,Child and Adolescent Health Service,Subiaco,Australia [4]Wesfarmers Centre for Vaccines and Infectious Diseases,Telethon Kids Institute,Nedlands,Australia [5]Pharmacy Department,King Edward Memorial Hospital,Women and Newborn Health Service,Western Australia,Australia [6]Curtin Health Innovation Research Institute,Curtin University,Bentley,Australia

出　　处：《Pediatric Investigation》2023年第4期263-267,共5页儿科学研究（英文）

基　　金：Women&Infants Research Foundation;Department of Pharmacy at King Edward Memorial Hospital for Women。

摘　　要：Pentoxifylline(PTX)is reported to provide beneficial outcomes in the treatment of neonatal sepsis and serious inflammatory conditions.1,2 In the neonatal intensive care setting,PTX is administered by intravenous(IV)infusion and is routinely co-administered via Ysite with other parenteral medications and/or fluids.Although the physicochemical compatibility of PTX with a range of parenteral drugs,IV fluids,and lipid-free parenteral nutrition solutions has been reported,there is an emerging demand for more PTX compatibility data against previously untested medications(ampicillin,cloxacillin,fentanyl,fluconazole,furosemide,hydrocortisone,and ibuprofen lysine)and high-concentration IV drugs(alprostadil,dopamine,epinephrine,midazolam,milrinone,morphine,and norepinephrine)which may be used in fluid-restricted,vulnerable patients.3–5 In order to address this requirement for contemporary information,we investigated the physical and chemical compatibility of PTX with a panel of 20 drugs,in 51 PTX-drug combinations.

关 键 词：PARENTERAL DRUGS INJECTION 

分 类 号：R96[医药卫生—药理学]